Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cellestis' tuberculosis diagnostic:

This article was originally published in Clinica

Executive Summary

Melbourne, Australia-based Cellestis has received regulatory approval in South Korea for its tuberculosis (TB) diagnostic, QuantiFERON-TB Gold In-Tube. The test is based on the measurement of IFN-gamma secreted from stimulated T cell lymphocytes previously exposed to Mycobacterium tuberculosis infection. The assay involves an overnight culture of whole blood with tuberculin and control antigens, followed by detection of IFN-gamma in a rapid, single-step, sandwich ELISA. The prevalence of TB in Korea has been reported as 135 per 100,000 people, and BCG vaccination is mandatory. Cellestis will market the test in the Korea via its distributor, Woongbee MeDiTech.

You may also be interested in...

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.

Start-Up Spotlight: Iraq War Veteran Deploys ‘Bone Paint’ To Combat Traumatic Injuries

Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts